Miruvor
Sign up
The short answer

What studies of IV saline and fluids found

8papers on IV saline and fluids
24people in 3 studies testing IV saline and fluids alone
0randomised trials, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 7 findings, all C.

7 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: IV saline and fluids might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 8 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. IV saline and fluids · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Autonomic symptoms3 studies · 24 people took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (24 in all); not all results were tested against chance; only people who finished were analysed; the studies disagree.

Studies with no comparison group3 studies · 24 people with results

Autonomic symptoms improved.

The evidence is very uncertain about the effect of IV saline and fluids on autonomic symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (24 in all)
  • Not all results were tested against chance
  • Only people who finished were analysed
  • The studies disagree
See the 3 studies
  1. Cardiopulmonary responses to exercise in an individual with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome during long-term treatment with intravenous saline: A case study. (2020)

    People in the study
    1 in the study
    Dose
    1 L, daily for 678 days
    Outcome
    SBP Peak (mmHg)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Beneficial effects of intermittent intravenous saline infusion in dysautonomic patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: a case-series. (2025)

    People in the study
    40 in the study · 22 with outcome data
    Dose
    1,000–2000 mL, every third week over 9 weeks (i.e., a maximum of 3 infusions)
    Outcome
    SBP and DBP during treatment sessions
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome (2006)

    People in the study
    1 in the study
    Dose
    1 L/day, chronic administration
    Outcome
    heart rate (HR)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 1 (few people) person took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at 15, 55, 92, 125, 180, 249 and 417 days post first treatment · 1 L/day, chronic administration (few people)

Breathlessness improved.

The evidence is very uncertain about the effect of IV saline and fluids on breathlessness in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome (2006)

    People in the study
    1 in the study
    Dose
    1 L/day, chronic administration
    Outcome
    minute ventilation (VE)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at 15, 55, 92, 125, 180, 249 and 417 days post first treatment · 1 L/day, chronic administration (few people)

Fatigue improved.

The evidence is very uncertain about the effect of IV saline and fluids on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome (2006)

    People in the study
    1 in the study
    Dose
    1 L/day, chronic administration
    Outcome
    fatigue
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at 15, 55, 92, 125, 180, 249 and 417 days post first treatment · 1 L/day, chronic administration (few people)

Pain improved.

The evidence is very uncertain about the effect of IV saline and fluids on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome (2006)

    People in the study
    1 in the study
    Dose
    1 L/day, chronic administration
    Outcome
    muscle pain
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Post-exertional malaise1 study · 1 (few people) person took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 678 days · 1 L, daily for 678 days (few people)

Post-exertional malaise improved.

The evidence is very uncertain about the effect of IV saline and fluids on post-exertional malaise in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Cardiopulmonary responses to exercise in an individual with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome during long-term treatment with intravenous saline: A case study. (2020)

    People in the study
    1 in the study
    Dose
    1 L, daily for 678 days
    Outcome
    Self-reported recovery time from CPET
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 22 people took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all); only people who finished were analysed.

Studies with no comparison group40 in the study · 22 with outcome data · over 9 weeks · 1,000–2000 mL, every third week over 9 weeks (i.e., a maximum of 3 infusions)

Overall symptoms improved.

The evidence is very uncertain about the effect of IV saline and fluids on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (22 in all)
  • Only people who finished were analysed
See the 1 study
  1. Beneficial effects of intermittent intravenous saline infusion in dysautonomic patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: a case-series. (2025)

    People in the study
    40 in the study · 22 with outcome data
    Dose
    1,000–2000 mL, every third week over 9 weeks (i.e., a maximum of 3 infusions)
    Outcome
    composite symptom score
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning1 study · 1 (few people) person took IV saline and fluids Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at 15, 55, 92, 125, 180, 249 and 417 days post first treatment · 1 L/day, chronic administration (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of IV saline and fluids on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome (2006)

    People in the study
    1 in the study
    Dose
    1 L/day, chronic administration
    Outcome
    activity tolerance
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Worse symptoms or a flare1 study

All papers

  1. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  2. Beneficial effects of intermittent intravenous saline infusion in dysautonomic patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: a case-series.2025 · no comparison group · 40 in the study · 22 with outcome data
    Summary

    This non-controlled case-series examined intermittent intravenous saline in adults with ME/CFS and dysautonomia and/or hypovolemia in Stockholm. Of 40 patients considered, 18 were treated only once or twice and did not complete; data focused on 22 who completed all three treatments over 9 weeks. Saline (9 mg/mL NaCl) was given intravenously every third week, final volume 1,000–2000 mL, mean 1,600 ± 360 mL over three occasions. No comparison group was used; outcomes were assessed before and after treatment. Outcomes included composite symptom score (0–96), POTS score (0–120), quality-of-life (0–100), working ability (0–100), tilt testing, vital signs and side-effects, with follow-up 1 week after treatment. Mean composite symptom score decreased from 47 ± 13 to 34 ± 11 (p < 0.001); median POTS score from 64 (IQR 16) to 43 (IQR 29) (p < 0.001); median quality-of-life from 25 (IQR 25) to 50 (IQR 15) (p < 0.001); median working ability from 0 (IQR 25) to 15 (IQR 35) (p < 0.05). Among 19 responders, mean benefit was 5.5 ± 2.4 on a 0–10 scale. Heart rate changed by −11 bpm (SD 10; p = 0.02), while SBP and DBP were unchanged; POTS diagnosis was unaffected. Infusions were well tolerated; no serious side-effects were reported. One patient reported a treatment-related decrease in quality-of-life and working ability, and none reported worsening POTS symptoms. Fourteen individuals (64%) reported PEM, one severe. Authors state the series was non-controlled and small, with no sustainable effects detected and need for a randomized, blinded trial.

  3. Plasma Exchange Improves Cognitive Function in Long-COVID-Related Postural Orthostatic Tachycardia Syndrome and Autoimmune Neurological Dysfunction.2025 · case report · 1 in the study
    Summary

    This case report describes one previously well 37-year-old female with long-COVID-related postural orthostatic tachycardia syndrome and autoimmune neurological dysfunction. The paper reports that plasma exchange was given as a 3-liter exchange with donated 4% human albumin daily for 5 consecutive days via an internal jugular vein vascath, with heparin at 1,000 IU/h during the plasma exchange. There was no comparison group; outcomes were reported before and after treatment. The paper reports marked improvement in dysarthria and in speed and fluency of speech following the first day, and cognitive function markedly improved across all domains after 5 days as assessed with Montreal Cognitive Assessment (MoCA) and Cambridge Neuropsychological Test Automated Battery (CANTAB). Table values include reaction time 1,447 to 398 ms (72%), rapid visual information processing 21 to 39 (85%), multitasking reaction latency 278 to 86 ms (69%), multitasking total correct 76 to 156 (105%), delayed matching latency 10,782 to 2,889 ms (73%), delayed matching correct 12 to 19 (58%), and MoCA total 24/30 to 30/30 (25%); some MoCA domains are printed as identical before and after. Improvements in peripheral pain and supervised ambulatory tolerance (from 5 to 12 meters) are reported. Similar benefits were seen with 2 further courses over the ensuing months with no complications. The authors state: "It remains unclear whether the acute cognitive and speech improvements with the use of plasma exchange and subsequent benefits of repeat plasma exchange therapy were related to changes in cerebral perfusion."

  4. Clinically Meaningful Improvements in Long COVID Symptoms Following Ketogenic Metabolic Therapy Combined with Lifestyle Interventions-A Clinical Case Report and Review of the Literature.2025 · case report · 1 in the study
    Summary

    This case report describes one patient with Long COVID, POTS and ME/CFS at the OHSU Long COVID Clinic who enrolled in a community-based 12-week educational program. The program combined a ketogenic diet (low-carbohydrate and moderate-protein intake) with daily activities to entrain circadian rhythm, mindfulness-based strategies, and group health coaching; the patient also received thiamine 2000 mg/day and magnesium 3000 mg. No comparison group was reported. Clinical improvements were identified in five of the seven patient-reported measures across dysautonomia, shortness of breath, migraine disability, fatigue, and physical function. Within the first two weeks, chronic hypotension resolved and IV saline therapy was discontinued; she reported increased energy coinciding with ketosis. By the second month, sound and light sensitivity resolved, menstrual cycle normalized to 25 - 29 days, and headaches reduced from 4 - 5 times per week to once or twice a month. PEM after moderate exertion continued, while flushing episodes were diminished. Over 12 weeks, she lost 15% of body weight and BMI changed from 23 to 20 kg/m2; by month seven she worked cognitively 5 - 6 hours per day and exercised 20 minutes daily without triggering PEM, with BMI stabilizing at 21 kg/m. The patient did not report experiencing possible adverse reactions to KMT or vitamin supplementation. The authors state that whether observed benefits are attributed to the interventions or external factors such as placebo effect or natural disease progression cannot be determined, that the most impactful component is difficult to determine, and that results cannot be generalized.

  5. Cardiopulmonary responses to exercise in an individual with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome during long-term treatment with intravenous saline: A case study.2020 · case report · 1 in the study
    Summary

    This case study examined repeated intravenous saline in one 38-year-old female with ME/CFS diagnosed by an internal medicine physician according to the International Consensus Criteria. The patient received 1 L of 0.9% saline solution daily by central venous line; the abstract reports treatment for a total of 675 days, while the intervention section reports 678 days. There was no comparison group. Single cardiopulmonary exercise tests were completed periodically at days 15, 55, 92, 125, 180, 248, 317, 420, and 675, plus day 708, 30 days after the last infusion. An open-ended symptom questionnaire assessed subjective responses and recovery time. Reported within-patient changes included peak VO2 from 23.7 to 32.3 ml/kg/min, peak HR from 158 to 189 beats/min, and peak SBP from 115 mmHg to 174 mmHg after 420 days. Self-reported recovery time from CPET reduced from 5 days to 1–2 days by the end of treatment. The authors report reduced brain fog, improved quality of life, improved capacity for activities of daily living, and reduced symptoms; the patient was unable to resume her pre-illness level of occupational activity. After treatment cessation, VO2 decreased at peak exertion and ventilatory anaerobic threshold; HR and SBP remained above pre-infusion levels, and symptoms remained improved overall. The authors report little to no side effects compared with other pharmaceutical interventions and note bacteremia as a known risk associated with IV treatment. They state that duration and dosage remain unknown and that generalizability is unknown.

  6. Intravenous saline administration improves physical functioning.2007 · case report · 1 in the study
    Summary

    This abstract reports a study of intravenous 0.9% saline at 1 L/day in one 37 yr old female with Chronic Fatigue Syndrome (CFS). The stated purpose was to investigate the effect of 1 L/day of 0.9% saline administration in this patient. Primary outcome measures were based on cardiopulmonary responses during maximal exercise testing. A preliminary exercise test was performed before saline administration, and follow-up exercise tests were conducted at 15, 55, 92, 125, 180, 248, 317, 420 and 675 days post first treatment and 30 days post last treatment. The abstract does not report a comparison group, the duration of saline administration, harms, withdrawals, or worsening. It reports that measures of peak oxygen consumption (VO2 peak), minute ventilation (VE), VO2 at anaerobic threshold (AT), peak workload (WL), heart rate (HR), and systolic blood pressure (SBP) increased during the saline administration. It does not report significance for these measures. The authors conclude that chronic infusion of fluids improves the disease associated hypovolemia, thereby improving CFS symptomology. No limitations are stated in the abstract.

  7. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome2006 · case report · 1 in the study
    Summary

    This abstract reports a single-patient study in Chronic Fatigue Syndrome (CFS). The purpose was to determine if chronic administration of intravenous saline improves performance during graded exercise testing in a patient with CFS. The patient was a 38 yr old female. Following baseline cardiopulmonary exercise testing, she was administered 1 L/day of 0.9% saline via central venous line. Further exercise tests were conducted at 15, 55, 92, 125, 180, 249 and 417 days post first treatment. Measures of peak oxygen consumption (VO2 peak), minute ventilation (VE), VO2 at anaerobic threshold (AT), peak workload (WL), heart rate (HR), and systolic blood pressure (SBP) were compared across all tests. No comparison group is reported. The abstract states that improved performance was observed following saline administration (see table). Increases in performance were accompanied by increases in VE, HR, and SBP. During saline administration the subject reported improved activity tolerance, reduced muscle pain and fatigue, and improved orthostatic tolerance. The abstract does not report side effects, withdrawals, or a stated limitation.

  8. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment.2024 · review
    Summary

    This literature review searched EBSCOhost Academic Search Premier, Proquest, Google Scholar, and the Cochrane Library in June 2022 for published treatments for chronic inflammatory response syndrome (CIRS), ME/CFS, and sick building syndrome. No patients were enrolled by the review; no comparison group, randomization, or follow-up duration was reported. The review reports 13 articles comprising 14 studies on CIRS treatment and also reviews CFS treatment studies. Named CIRS study sizes included 8, 13, 28, 14, 21, 156/111, 20, 35/4, 100, and 68/23. The review states the only treatment with documented clinical efficacy was the Shoemaker Protocol, described in 11 of the 13 articles; table entries list cholestyramine and vasoactive intestinal peptide as successful, while Rea’s antigen intradermal treatments had lack of objective data. CFS studies listed sizes including 49, 1518, 1030, 2036, 62, 409, 101, 171, 33, 32/18, 23, and 218; findings included some benefit for aripiprazole in 101 patients, high frequency of response for low-dose naltrexone in 218, and CBT/GET reported beneficial in six studies but noncurative. Reported side effects include constipation from cholestyramine, hyponatremia from desmopressin, and light-headedness from vasoactive intestinal peptides; medication intolerance was a barrier.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime